01549nas a2200361   4500000000100000008004100001260001600042653001600058653000900074653001100083653001200094653002000106653001100126653001100137653001100148653003200159653002100191653001000212653001600222653001000238653001500248100001200263700001900275700001200294700001700306700001200323245006700335856009900402300001200501490000600513520065400519022001401173       1986                            d  c1986 Aug 3010aVaccination10aMale10aMalawi10aleprosy10aInfant, Newborn10aInfant10aHumans10aFemale10aEvaluation Studies as Topic10aChild, Preschool10aChild10aBCG Vaccine10aAdult10aAdolescent1 aFine PE1 aPonnighaus J M1 aMaine N1 aClarkson J A1 aBliss L00aProtective efficacy of BCG against leprosy in Northern Malawi.  uhttp://www.med.mcgill.ca/epidemiology/Hanley/bios601/CaseControlStudies/FineEtAlBCGleprosy.pdf  a499-5020 v23 a<p>The effectiveness of a BCG vaccination programme in protecting against leprosy was assessed by case-control and cohort analyses of data from the Lepra Evaluation Project in Karonga District, Northern Malawi. Results indicate that BCG provides at least 50% protection against leprosy in this population and that protection is independent of age, sex, schooling status, or location within the project area. Agreement between these findings and those from a controlled trial in Uganda indicates that BCG is sufficiently effective against leprosy in East and Central Africa to be considered an important element of leprosy control in that region.</p>  a0140-6736